Research ExplorerPublicationsPhase I trial of SU14813 in patients with advanced solid mal...

Phase I trial of SU14813 in patients with advanced solid malignancies.

Standard

Phase I trial of SU14813 in patients with advanced solid malignancies. / Fiedler, Walter; Giaccone, G; Lasch, P; van der Horst, I; Brega, N; Courtney, R; Abbattista, A; Shalinsky, D R; Bokemeyer, Carsten; Boven, E.

In: ANN ONCOL, Vol. 22, No. 1, 1, 2011, p. 195-201.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Fiedler, W, Giaccone, G, Lasch, P, van der Horst, I, Brega, N, Courtney, R, Abbattista, A, Shalinsky, DR, Bokemeyer, C & Boven, E 2011, 'Phase I trial of SU14813 in patients with advanced solid malignancies.', ANN ONCOL, vol. 22, no. 1, 1, pp. 195-201. <http://www.ncbi.nlm.nih.gov/pubmed/20605934?dopt=Citation>

APA

Fiedler, W., Giaccone, G., Lasch, P., van der Horst, I., Brega, N., Courtney, R., Abbattista, A., Shalinsky, D. R., Bokemeyer, C., & Boven, E. (2011). Phase I trial of SU14813 in patients with advanced solid malignancies. ANN ONCOL, 22(1), 195-201. [1]. http://www.ncbi.nlm.nih.gov/pubmed/20605934?dopt=Citation

Vancouver

Fiedler W, Giaccone G, Lasch P, van der Horst I, Brega N, Courtney R et al. Phase I trial of SU14813 in patients with advanced solid malignancies. ANN ONCOL. 2011;22(1):195-201. 1.

Bibtex

@article{f563a57cb3ad4804a4dd87c81b8503f5,
title = "Phase I trial of SU14813 in patients with advanced solid malignancies.",
abstract = "this phase I, open-label, dose-escalation study investigated SU14813, an oral multitargeted tyrosine kinase inhibitor, in adults with solid tumors.",
author = "Walter Fiedler and G Giaccone and P Lasch and {van der Horst}, I and N Brega and R Courtney and A Abbattista and Shalinsky, {D R} and Carsten Bokemeyer and E Boven",
year = "2011",
language = "Deutsch",
volume = "22",
pages = "195--201",
journal = "ANN ONCOL",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Phase I trial of SU14813 in patients with advanced solid malignancies.

AU - Fiedler, Walter

AU - Giaccone, G

AU - Lasch, P

AU - van der Horst, I

AU - Brega, N

AU - Courtney, R

AU - Abbattista, A

AU - Shalinsky, D R

AU - Bokemeyer, Carsten

AU - Boven, E

PY - 2011

Y1 - 2011

N2 - this phase I, open-label, dose-escalation study investigated SU14813, an oral multitargeted tyrosine kinase inhibitor, in adults with solid tumors.

AB - this phase I, open-label, dose-escalation study investigated SU14813, an oral multitargeted tyrosine kinase inhibitor, in adults with solid tumors.

M3 - SCORING: Zeitschriftenaufsatz

VL - 22

SP - 195

EP - 201

JO - ANN ONCOL

JF - ANN ONCOL

SN - 0923-7534

IS - 1

M1 - 1

ER -